What Compass Therapeutics Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 2 | 4 |
| Sells | 0 | 0 |
| Total trades | 2 | 11 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 22,500 | 650,000 |
| Disposed | 0 | 127,489 |
| Net activity | +22,500 | +522,511 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Lerner Neil | Chief Accounting Officer | Oct 01 | Open-market buy · P | +20,000 | $0.92 | +$18.4K | 420,000 |
| Lerner Neil | Chief Accounting Officer | Sep 24 | Open-market buy · P | +2,500 | $1.14 | +$2.85K | 400,000 |
| Lerner Neil | Chief Accounting Officer | Apr 29 | Open-market buy · P | +15,000 | $1.89 | +$28.4K | 397,500 |
| Anderman Jonathan | General Counsel | Apr 29 | Open-market buy · P | +25,000 | $1.89 | +$47.3K | 196,000 |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Feb 08 | Withheld — tax / exercise cost · F | −36,687 | $6.52 | −$239K | 6,603,336 |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Jan 09 | Withheld — tax / exercise cost · F | −46,777 | $5.35 | −$250K | 6,640,023 |
| Anderman Jonathan | General Counsel | Jan 02 | Grant / award · A | +150,000 | $5.17 | +$776K | 171,000 |
| Lerner Neil | Chief Accounting Officer | Jan 02 | Grant / award · A | +62,500 | $5.17 | +$323K | 382,500 |
| Schuetz Thomas J. | CEO | Jan 02 | Grant / award · A | +250,000 | $5.17 | +$1.29M | 6,686,800 |
| Shin Barry | CFO | Jan 02 | Grant / award · A | +125,000 | $5.17 | +$646K | 525,000 |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Nov 16 | Withheld — tax / exercise cost · F | −44,025 | $4.83 | −$213K | 6,436,800 |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | May 27 | Open-market buy · P | +10,000 | $2.11 | +$21.1K | 6,480,825 |
| Gordon Carl L | Director | Apr 09 | Open-market sale · S | −3,571,428 | $1.59 | −$5.68M | 0 |
| Orbimed Advisors Llc | Director | Apr 09 | Open-market sale · S | −3,571,428 | $1.59 | −$5.68M | 0 |
| Lerner Neil | CHIEF ACCOUNTING OFFICER | Apr 07 | Open-market buy · P | +20,000 | $1.42 | +$28.4K | 320,000 |
| Anderman Jonathan | Gen Counsel & Corporate Sec | Apr 07 | Open-market buy · P | +20,000 | $1.54 | +$30.8K | 21,000 |
| Schuetz Thomas J. | CEO | Feb 08 | Withheld — tax / exercise cost · F | −41,687 | $3.50 | −$146K | 6,470,825 |
| Schuetz Thomas J. | CEO | Jan 09 | Withheld — tax / exercise cost · F | −58,054 | $1.86 | −$108K | 6,512,512 |
| Shin Barry | CFO | Dec 09 | Grant / award · A | +400,000 | $1.65 | +$660K | 400,000 |
| Schuetz Thomas J. | PRESIDENT | Feb 08 | Withheld — tax / exercise cost · F | −44,782 | $1.45 | −$64.9K | 6,570,566 |
Loading...
